Robin Cornelissen

7.5k total citations · 2 hit papers
98 papers, 1.9k citations indexed

About

Robin Cornelissen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Robin Cornelissen has authored 98 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 13 papers in Biotechnology. Recurrent topics in Robin Cornelissen's work include Occupational and environmental lung diseases (41 papers), Lung Cancer Treatments and Mutations (28 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Robin Cornelissen is often cited by papers focused on Occupational and environmental lung diseases (41 papers), Lung Cancer Treatments and Mutations (28 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Robin Cornelissen collaborates with scholars based in Netherlands, United States and Italy. Robin Cornelissen's co-authors include Joachim G.J.V. Aerts, Joost P. Hegmans, Lysanne A. Lievense, Rudi W. Hendriks, Koen Bezemer, Henk C. Hoogsteden, Alexander P.W.M. Maat, Daphne W. Dumoulin, Margaretha E.H. Kaijen-Lambers and Paul Baas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Robin Cornelissen

92 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

2022 158 citations Solange Peters, Arnaud Scherpereel et al. Annals of Oncology profile →
LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers

Robin Cornelissen

PRM

ONCOL

IMMUN

Héctor Soto Parrà Italy

Giulia Pasello Italy

Andrew Dean Australia

Jessica Menis Italy

Ryan D. Gentzler United States

Jean-Louis Pujol France

M. Duruisseaux France

Fatima Karzai United States

Daniel L. Suzman United States

Aurélie Bertaut France

Héctor Soto Parrà Italy

Robin Cornelissen

1.6k ×1.2

PRM

1.3k ×1.4

ONCOL

129 ×0.4

IMMUN

258 ×1.2

150 ×0.9

Citations per year, relative to Robin Cornelissen Robin Cornelissen (= 1×) peers Héctor Soto Parrà

Countries citing papers authored by Robin Cornelissen

Since Specialization

Citations

This map shows the geographic impact of Robin Cornelissen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Cornelissen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Cornelissen more than expected).

Fields of papers citing papers by Robin Cornelissen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Cornelissen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Cornelissen. The network helps show where Robin Cornelissen may publish in the future.

Co-authorship network of co-authors of Robin Cornelissen

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Cornelissen. A scholar is included among the top collaborators of Robin Cornelissen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Cornelissen. Robin Cornelissen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Provencio, Mariano, Mark M. Awad, Tina Cascone, et al.. (2024). LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Annals of Oncology. 35. S1239–S1240. 9 indexed citations

Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations

Granton, Patrick V., Steven Petit, J. Belderbos, et al.. (2024). 740: High survival after high dose reirradiation of in-field recurrent lung cancer: a prospective trial. Radiotherapy and Oncology. 194. S1622–S1625.

Paats, Marthe S., Joachim G.J.V. Aerts, Daphne W. Dumoulin, et al.. (2024). Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. EBioMedicine. 102. 105074–105074. 13 indexed citations

Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations

Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →

Ahn, M-J., Aaron Lisberg, Luis Paz‐Ares, et al.. (2023). LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. Annals of Oncology. 34. S1305–S1306. 34 indexed citations

Dumoulin, Daphne W., Luca Cantini, Robin Cornelissen, et al.. (2022). Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma. European Journal of Cancer. 172. 357–366. 10 indexed citations

Wait, Suzanne, Arturo Álvarez-Rosete, Tasnime Osama, et al.. (2022). Implementing Lung Cancer Screening in Europe: Taking a Systems Approach. JTO Clinical and Research Reports. 3(5). 100329–100329. 38 indexed citations

10.

Zalcman, Gérard, Robin Cornelissen, Laurent Greillier, et al.. (2022). LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Annals of Oncology. 33. S1438–S1439. 5 indexed citations

11.

Dumoulin, Daphne W., Robin Cornelissen, Koen Bezemer, Sara J. Baart, & Joachim G.J.V. Aerts. (2021). Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines. 9(5). 525–525. 14 indexed citations

12.

Cornelissen, Robin, Sanyuan Sun, Marina Chiara Garassino, et al.. (2021). LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). Annals of Oncology. 32. S1324–S1324. 6 indexed citations

13.

Vroman, Heleen, Robert A. Belderbos, Paul L. Klarenbeek, et al.. (2020). T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. Journal for ImmunoTherapy of Cancer. 8(1). e000251–e000251. 23 indexed citations

14.

Vroman, Heleen, et al.. (2020). PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients. Cancer Immunology Immunotherapy. 70(2). 453–461. 20 indexed citations

15.

Baas, Paul, Arnaud Scherpereel, Anna K. Nowak, et al.. (2020). ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Thoracic Oncology. 15(10). e42–e42. 37 indexed citations

16.

Belderbos, Robert A., Floris Dammeijer, Mandy van Gulijk, et al.. (2019). MA12.09 Checkpoint Inhibitors Synergize with Dendritic Cell-Therapy in Pre-Clinical Models and Mesothelioma Patients. Journal of Thoracic Oncology. 14(10). S298–S299. 2 indexed citations

17.

Aerts, Joachim G.J.V., Pauline L. de Goeje, Robin Cornelissen, et al.. (2017). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research. 24(4). 766–776. 71 indexed citations

18.

Lievense, Lysanne A., Daniel H. Sterman, Robin Cornelissen, & Joachim G.J.V. Aerts. (2017). Checkpoint Blockade in Lung Cancer and Mesothelioma. American Journal of Respiratory and Critical Care Medicine. 196(3). 274–282. 54 indexed citations

19.

Lievense, Lysanne A., Koen Bezemer, Robin Cornelissen, et al.. (2016). Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. Lung Cancer. 107. 36–40. 15 indexed citations

20.

Cornelissen, Robin, Joost P. Hegmans, Alexander P.W.M. Maat, et al.. (2015). Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine. 193(9). 1023–1031. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact